



EXPRESS SCRIPTS®

**Express Scripts, Inc.  
Pharmacy and Therapeutics Committee  
Proceedings  
May 13, 2010**

**New Drug Evaluations**

The Committee reviewed the following new drugs.

- A. **Exalgo™ (hydromorphone HCl extended release tablets - Alza/Covidien)**
- B. **Oravig™ (miconazole buccal tablet – Strativa/Par)**
- C. **Xifaxan® (rifaximin tablets – Salix) – new strength and indication**
- D. **Zortress® (everolimus tablets – Novartis)**
- E. **Zyprexa® Relprevv™ (olanzapine for extended-release injectable suspension – Eli Lilly.)**

**New Indications for Existing Products**

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. **Creon® (pancrelipase delayed-release capsules, enteric-coated) Abbott** – For treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy or other conditions.
- B. **Mirapex® ER® (pramipexole extended-release tablets) Boehringer Ingelheim** - For the treatment of the signs and symptoms of idiopathic Parkinson's disease.
- C. **Tarceva® (erlotinib tablets) Genentech/OSI oncology** – For the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- D. **Xifaxan® (rifaximin 550 mg tablets) Salix** - For the reduction in risk of overt hepatic encephalopathy recurrence in patients aged  $\geq 18$  years.

**New Clinical Line Extensions**

The Committee reviewed the following new clinical line extensions.

- A. **Differin® (adapalene lotion, 0.1%) Galderma**
- B. **Epoprostenol for injection – Actelion**
- C. **Pancreaze™ (pancrelipase delayed-release [enteric coated] capsules) McNeil Pediatrics/ Ortho-McNeil-Janssen**
- D. **Vimovo™ (naproxen and esomeprazole magnesium delayed-release tablets) AstraZeneca**
- E. **Zyclara™ (imiquimod cream, 3.75%) Graceway**